deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02999178

Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) (INBUILD®)

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Sponsor: Boehringer Ingelheim

Conditions Lung Diseases, Interstitial
Interventions Nintedanib Placebo
Updated 30 times since 2017 Last updated: Apr 22, 2020 Started: Jan 17, 2017 Primary completion: Apr 23, 2019 Completion: Aug 12, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Lung Diseases, Interstitial and is currently completed. Boehringer Ingelheim leads this study, which shows 30 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Jun 2020 · 6 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

30 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2020 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 25 earlier versions

  1. Dec 2019 — Jun 2020 [monthly]

    Completed PHASE3

  2. Sep 2019 — Dec 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Aug 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE3

  5. Apr 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Nov 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Aug 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  10. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  11. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  12. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE3

  13. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE3

  14. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  15. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE3

  16. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  17. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  18. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  19. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  20. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  21. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  22. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE3

  23. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  24. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  25. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Seto, Japan , Alberdi Sur, Argentina , Angleur, Belgium , Ann Arbor, United States , Atlanta, United States , Baltimore, United States , Barcelona, Spain , Beijing, China , Birmingham, United States , Bobigny, France and 129 more locations